CD86 (Dendritic Cells Maturation Marker) Antibody - With BSA and Azide
Purified Mouse Monoclonal Antibody
|Application ||IHC, IF, FC, IP, E|
|Reactivity||Human, Mouse, Rat|
|Other Names||T-lymphocyte activation antigen CD86, Activation B7-2 antigen, B70, BU63, CTLA-4 counter-receptor B72, FUN-1, CD86, CD86, CD28LG2|
|Target/Specificity||ARH-77 (B-lymphoblastoid cell line)|
|Application Note||ELISA : For coating, order Ab without BSA|
Functional Studies : Order Ab without Azide
Flow Cytometry : 0.5-1ug/million cells
Immunofluorescence : 0.5-1.0 µg/ml
Western Blotting : 0.5-1.0 µg/ml
Immunoprecipitation : 0.5-1 µg/500ug protein lysate
Immunohistology (Frozen) : 0.5-1.0 µg/ml for 30 minutes at RT.
|Format||0.5 ml at 200ug/ml with BSA and azide|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||CD86 (Dendritic Cells Maturation Marker) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Receptor involved in the costimulatory signal essential for T-lymphocyte proliferation and interleukin-2 production, by binding CD28 or CTLA-4. May play a critical role in the early events of T-cell activation and costimulation of naive T-cells, such as deciding between immunity and anergy that is made by T- cells within 24 hours after activation. Isoform 2 interferes with the formation of CD86 clusters, and thus acts as a negative regulator of T-cell activation.|
|Cellular Location||Cell membrane; Single-pass type I membrane protein|
|Tissue Location||Expressed by activated B-lymphocytes and monocytes|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Recognizes a protein of 70kDa, which is identified as CD86 (HLDA V; WS Code BP BP072. HLDA V; WS Code A A109. HLDA VI; WS Code BP 95. HLDA VI; WS Code B CD86.9). CD86 is a type I transmembrane glycoprotein and a member of the immunoglobulin superfamily of cell surface receptors. It is expressed at high levels on resting peripheral monocytes and dendritic cells and at very low density on resting B and T lymphocytes. CD86 expression is rapidly upregulated by B cell specific stimuli with peak expression at 18 to 42 hours after stimulation. CD86, along with CD80/B71, is an important accessory molecule in T cell co-stimulation via its interaction with CD28 and CD152/CTLA4. Since CD86 has rapid kinetics of induction, it is believed to be the major CD28 ligand expressed early in the immune response. It is also found on malignant Hodgkin and Reed Sternberg (HRS) cells in Hodgkin's disease.
1. Engel P, Gribben JG, Freeman GJ, Zhou LJ, Nozawa Y, Abe M, Nadler LM, Wakasa H, Tedder TF: The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen. Blood. 1994;84(5):1402-7.
2. Caux C, Vanbervliet B, Massacrier C, Azuma M, Okumura K, Lanier LL, Banchereau J: B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J Exp Med. 1994;180(5):1841-7.
3. Mauri D, Wyss-Coray T, Gallati H, Pichler WJ: Antigen-presenting T cells induce the development of cytotoxic CD4+ T cells. I. Involvement of the CD80-CD28 adhesion molecules. J Immunol. 1995;155(1):118-27.
4. Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995).
5. Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.